 The RAVE Rubeosis Anit-VEgf trial, utilizes monthly intravitreal Ranibizumab Lucentis injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and eliminate the need for panretinal photocoagulation in patients with ischemic central retinal vein occlusion. 